Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities

Ioanna Andreadou, Hector A. Cabrera-Fuentes, Yvan Devaux, Nikolaos G. Frangogiannis, Stefan Frantz, Tomasz Guzik, Elisa A. Liehn, Clarissa P.C. Gomes, Rainer Schulz, Derek J. Hausenloy

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading causes of death and disability globally. In this regard, the immune cell response to AMI, which comprises an initial pro-inflammatory reaction followed by an anti-inflammatory phase, contributes to final MI size and post-AMI remodelling [changes in left ventricular (LV) size and function]. The transition between these two phases is critical in this regard, with a persistent and severe pro-inflammatory reaction leading to adverse LV remodelling and increased propensity for developing heart failure. In this review article, we provide an overview of the immune cells involved in orchestrating the complex and dynamic inflammatory response to AMI-these include neutrophils, monocytes/macrophages, and emerging players such as dendritic cells, lymphocytes, pericardial lymphoid cells, endothelial cells, and cardiac fibroblasts. We discuss potential reasons for past failures of anti-inflammatory cardioprotective therapies, and highlight new treatment targets for modulating the immune cell response to AMI, as a potential therapeutic strategy to improve clinical outcomes in AMI patients. This article is part of a Cardiovascular Research Spotlight Issue entitled 'Cardioprotection Beyond the Cardiomyocyte', and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.

Original languageEnglish (US)
Pages (from-to)1117-1130
Number of pages14
JournalCardiovascular research
Volume115
Issue number7
DOIs
StatePublished - Jun 1 2019

Fingerprint

Myocardial Infarction
Therapeutics
Anti-Inflammatory Agents
Heart Failure
Lymphocytes
Ventricular Remodeling
European Union
Left Ventricular Function
Cardiac Myocytes
Dendritic Cells
Monocytes
Cause of Death
Neutrophils
Endothelial Cells
Fibroblasts
Macrophages
Technology
Research

Keywords

  • Acute myocardial infarction
  • Dendritic cells
  • Fibroblasts
  • Inflammation
  • Lymphocytes
  • Macrophages
  • Monocytes
  • Myocardial ischaemia/reperfusion injury

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Andreadou, I., Cabrera-Fuentes, H. A., Devaux, Y., Frangogiannis, N. G., Frantz, S., Guzik, T., ... Hausenloy, D. J. (2019). Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular research, 115(7), 1117-1130. https://doi.org/10.1093/cvr/cvz050

Immune cells as targets for cardioprotection : new players and novel therapeutic opportunities. / Andreadou, Ioanna; Cabrera-Fuentes, Hector A.; Devaux, Yvan; Frangogiannis, Nikolaos G.; Frantz, Stefan; Guzik, Tomasz; Liehn, Elisa A.; Gomes, Clarissa P.C.; Schulz, Rainer; Hausenloy, Derek J.

In: Cardiovascular research, Vol. 115, No. 7, 01.06.2019, p. 1117-1130.

Research output: Contribution to journalArticle

Andreadou, I, Cabrera-Fuentes, HA, Devaux, Y, Frangogiannis, NG, Frantz, S, Guzik, T, Liehn, EA, Gomes, CPC, Schulz, R & Hausenloy, DJ 2019, 'Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities', Cardiovascular research, vol. 115, no. 7, pp. 1117-1130. https://doi.org/10.1093/cvr/cvz050
Andreadou, Ioanna ; Cabrera-Fuentes, Hector A. ; Devaux, Yvan ; Frangogiannis, Nikolaos G. ; Frantz, Stefan ; Guzik, Tomasz ; Liehn, Elisa A. ; Gomes, Clarissa P.C. ; Schulz, Rainer ; Hausenloy, Derek J. / Immune cells as targets for cardioprotection : new players and novel therapeutic opportunities. In: Cardiovascular research. 2019 ; Vol. 115, No. 7. pp. 1117-1130.
@article{4befa86ba2ca402895e78f10173e6162,
title = "Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities",
abstract = "New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading causes of death and disability globally. In this regard, the immune cell response to AMI, which comprises an initial pro-inflammatory reaction followed by an anti-inflammatory phase, contributes to final MI size and post-AMI remodelling [changes in left ventricular (LV) size and function]. The transition between these two phases is critical in this regard, with a persistent and severe pro-inflammatory reaction leading to adverse LV remodelling and increased propensity for developing heart failure. In this review article, we provide an overview of the immune cells involved in orchestrating the complex and dynamic inflammatory response to AMI-these include neutrophils, monocytes/macrophages, and emerging players such as dendritic cells, lymphocytes, pericardial lymphoid cells, endothelial cells, and cardiac fibroblasts. We discuss potential reasons for past failures of anti-inflammatory cardioprotective therapies, and highlight new treatment targets for modulating the immune cell response to AMI, as a potential therapeutic strategy to improve clinical outcomes in AMI patients. This article is part of a Cardiovascular Research Spotlight Issue entitled 'Cardioprotection Beyond the Cardiomyocyte', and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.",
keywords = "Acute myocardial infarction, Dendritic cells, Fibroblasts, Inflammation, Lymphocytes, Macrophages, Monocytes, Myocardial ischaemia/reperfusion injury",
author = "Ioanna Andreadou and Cabrera-Fuentes, {Hector A.} and Yvan Devaux and Frangogiannis, {Nikolaos G.} and Stefan Frantz and Tomasz Guzik and Liehn, {Elisa A.} and Gomes, {Clarissa P.C.} and Rainer Schulz and Hausenloy, {Derek J.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1093/cvr/cvz050",
language = "English (US)",
volume = "115",
pages = "1117--1130",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Immune cells as targets for cardioprotection

T2 - new players and novel therapeutic opportunities

AU - Andreadou, Ioanna

AU - Cabrera-Fuentes, Hector A.

AU - Devaux, Yvan

AU - Frangogiannis, Nikolaos G.

AU - Frantz, Stefan

AU - Guzik, Tomasz

AU - Liehn, Elisa A.

AU - Gomes, Clarissa P.C.

AU - Schulz, Rainer

AU - Hausenloy, Derek J.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading causes of death and disability globally. In this regard, the immune cell response to AMI, which comprises an initial pro-inflammatory reaction followed by an anti-inflammatory phase, contributes to final MI size and post-AMI remodelling [changes in left ventricular (LV) size and function]. The transition between these two phases is critical in this regard, with a persistent and severe pro-inflammatory reaction leading to adverse LV remodelling and increased propensity for developing heart failure. In this review article, we provide an overview of the immune cells involved in orchestrating the complex and dynamic inflammatory response to AMI-these include neutrophils, monocytes/macrophages, and emerging players such as dendritic cells, lymphocytes, pericardial lymphoid cells, endothelial cells, and cardiac fibroblasts. We discuss potential reasons for past failures of anti-inflammatory cardioprotective therapies, and highlight new treatment targets for modulating the immune cell response to AMI, as a potential therapeutic strategy to improve clinical outcomes in AMI patients. This article is part of a Cardiovascular Research Spotlight Issue entitled 'Cardioprotection Beyond the Cardiomyocyte', and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.

AB - New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading causes of death and disability globally. In this regard, the immune cell response to AMI, which comprises an initial pro-inflammatory reaction followed by an anti-inflammatory phase, contributes to final MI size and post-AMI remodelling [changes in left ventricular (LV) size and function]. The transition between these two phases is critical in this regard, with a persistent and severe pro-inflammatory reaction leading to adverse LV remodelling and increased propensity for developing heart failure. In this review article, we provide an overview of the immune cells involved in orchestrating the complex and dynamic inflammatory response to AMI-these include neutrophils, monocytes/macrophages, and emerging players such as dendritic cells, lymphocytes, pericardial lymphoid cells, endothelial cells, and cardiac fibroblasts. We discuss potential reasons for past failures of anti-inflammatory cardioprotective therapies, and highlight new treatment targets for modulating the immune cell response to AMI, as a potential therapeutic strategy to improve clinical outcomes in AMI patients. This article is part of a Cardiovascular Research Spotlight Issue entitled 'Cardioprotection Beyond the Cardiomyocyte', and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.

KW - Acute myocardial infarction

KW - Dendritic cells

KW - Fibroblasts

KW - Inflammation

KW - Lymphocytes

KW - Macrophages

KW - Monocytes

KW - Myocardial ischaemia/reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=85064087103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064087103&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvz050

DO - 10.1093/cvr/cvz050

M3 - Article

C2 - 30825305

AN - SCOPUS:85064087103

VL - 115

SP - 1117

EP - 1130

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 7

ER -